ROS1 and cancer: The interest in this pathway has gradually increased since the identification of two potent inhibitors, larotrectinib and entrectinib, with a wide spectrum of action and efficacy not only in NTRK altered cancer cells but also in cases where other altered genes are present, such as ALK or ROS1.